Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.63 |
| ▸ | RAF1 | P04049 | 9/20 | 0.63 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345995 | 1.00 | BRAF (0.63) | BRAFRAF1FAAHKDRABL1 | |
| SCHEMBL345458 | 0.90 | BRAF (0.64) | BRAFRAF1FAAHKDR | |
| SCHEMBL461378 | 0.90 | BRAF (0.64) | BRAFRAF1FAAHKDR | |
| SCHEMBL545665 | 0.87 | BRAF (0.60) | BRAFRAF1KDR | |
| SCHEMBL4679479 | 0.86 | BRAF (0.61) | BRAFRAF1KDRABL1 | |
| SCHEMBL10197660 | 0.86 | BRAF (0.59) | BRAFRAF1FAAHKDRABL1 | |
| SCHEMBL14493322 | 0.85 | BRAF (0.59) | BRAFRAF1KDR | |
| SCHEMBL545703 | 0.83 | BRAF (0.68) | BRAFRAF1FAAHKDR | |
| SCHEMBL24229489 | 0.82 | BRAF (0.51) | BRAFRAF1KDRABL1 | |
| SCHEMBL30515323 | 0.82 | BRAF (0.51) | BRAFRAF1KDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | BRAF 3601/4885RAF1 3360/4885FAAH 1791/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | BRAF 4293/4885RAF1 4055/4885FAAH 651/4885 |
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | BRAF 215/4885RAF1 198/4885FAAH 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.